Zeissig Mara N, Zannettino Andrew C W, Vandyke Kate
Myeloma Research Laboratory, Faculty of Health and Medical Sciences, Adelaide Medical School, The University of Australia, Adelaide 5005, Australia.
Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide 5000, Australia.
Cancers (Basel). 2020 Dec 4;12(12):3643. doi: 10.3390/cancers12123643.
Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral blood MM PCs are associated with rapid disease progression, shorter time to relapse and are a feature of advanced disease. In this review, the current understanding of the process of MM PC dissemination and the extrinsic and intrinsic factors potentially driving it are addressed through analysis of patient-derived MM PCs and MM cell lines as well as mouse models of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups that present with highly disseminated disease, such as t(4;14), t(14;16) and t(14;20), suggest that intrinsic properties of MM PC influence their ability to disseminate. Finally, we discuss the possibility of using therapeutic targeting of tumour dissemination to slow disease progression and prevent overt relapse.
多发性骨髓瘤(MM)是一种浆细胞(PC)恶性肿瘤,其特征是在整个骨髓的多个部位存在MM浆细胞。外周血MM浆细胞数量增加与疾病快速进展、较短的复发时间相关,是晚期疾病的一个特征。在本综述中,通过分析患者来源的MM浆细胞和MM细胞系以及归巢和播散的小鼠模型,探讨了目前对MM浆细胞播散过程以及可能驱动该过程的外在和内在因素的理解。此外,我们讨论了呈现高度播散性疾病的患者细胞遗传学亚组,如t(4;14)、t(14;16)和t(14;20),如何表明MM浆细胞的内在特性影响其播散能力。最后,我们讨论了利用肿瘤播散的治疗靶点来减缓疾病进展和预防明显复发的可能性。